ライフサイエンスコーパス: biologic therapy

1 en rheumatoid arthritis (RA) is treated with biologic therapy.

2 ally lower than noted in published trials of biologic therapy.

3 not recommended for use in combination with biologic therapy.

4 it to sensitize cells to chemotherapy or to biologic therapy.

5 Approximately 25% of patients received biologic therapy.

6 evaluate the varying prevalence and cost of biologic therapy.

7 all the patients also required some form of biologic therapy.

8 of serious and opportunistic infections with biologic therapy.

9 hritis has been revolutionized by the use of biologic therapy.

10 ing required when administering intravitreal biologic therapy.

11 patients with RA who were receiving anti-TNF biologic therapy.

12 locus predicts improved response to anti-TNF biologic therapy.

13 e guideline was narrowed to chemotherapy and biologic therapy.

14 ssociations were consistent across different biologic therapies.

15 ights form the conceptual basis for targeted biologic therapies.

16 mplications for the optimal use of expensive biologic therapies.

17 are amenable to treatment with drugs and/or biologic therapies.

18 rapeutic agents, somatostatin analogues, and biologic therapies.

19 ach to prevent the formation of ADAs against biologic therapies.

20 aking placebo, nonbiologic therapy, or other biologic therapies.

21 y act as a barometer of patient responses to biologic therapies.

22 Treatment of IBD is more and more based on biologic therapies.

23 d HBV (prHBV) infection undergoing long-term biologic therapies.

24 nd prevention of antidrug antibodies against biologic therapies.

25 0.001) when compared to IBD patients without biologic therapies.

26 ctious sequelae of both current and emerging biologic therapies.

27 views of factors that affect the response to biologic therapies.

28 A pathogenesis and developing targeted DMARD-biologic therapies.

29 oncern for patients with psoriasis receiving biologic therapies.

30 al and clinical safety testing of anti-IL-17 biologic therapies.

31 performance status, no prior chemotherapy or biologic therapy, adequate organ function, and measurabl

32 nclusion, drug survival rates differed among biologic therapies and decreased over time; second-line

33 We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent d

34 omide (LEF) monotherapy, in combination with biologic therapies and in combination with each other.

35 apidly evolving, with the induction of novel biologic therapies and newer, often more intensive treat

36 No association between biologic therapies and serious infections in patients wi

37 ul to stratify patients likely to respond to biologic therapies and to follow response to treatment.

38 financial and racial barriers to receipt of biologic therapies and underscores the need for addition

39 showed no significant difference between any biologic therapy and placebo at weeks 12-16 (overall poo

40 tients with psoriasis who had failed a first biologic therapy and switched to a second in a large, mu

41 ted among patients who had received previous biologic therapy and those who had not received such the

42 have important implications for anticytokine biologic therapy and vaccine development.

43 so discuss the implications for anticytokine biologic therapy and vaccine development.

44 mor necrosis factor-alpha, and 19 with other biologic therapies) and 959 patients without a prHBV inf

45 pipeline, including both small molecule and biologic therapies, and highlights the challenges associ

46 ne the advantages of both small-molecule and biologic therapies, and may address many drawbacks assoc

47 tlines treatment indications and forthcoming biologic therapy, and discusses challenges to performing

48 agents compared with chemotherapy, targeted biologic therapy, and treatment of premenopausal women.

49 ime course; radiosensitization by chemo- and biologic therapy; and the addition of novel, biologicall

50 d more are bound to surface, especially when biologic therapies are added to the armamentarium.

51 Biologic therapies are beginning to be explored as adjun

52 Current biologic therapies are beneficial in only a portion of p

53 However, the currently available biologic therapies are clearly not the panacea we have d

54 In 2014, new biologic therapies are emerging for severe asthma based

55 ic diseases are not yet fully characterized, biologic therapies are in development for the treatment

56 involves immunosuppressive drugs, including biologic therapy, as well as intravenous immunoglobulin,

57 ents were ineligible for subsequent targeted biologic therapy based on LVEF decline post-ddAC.

58 a risk : benefit profile at least similar to biologic therapies, be more convenient for the patient a

59 Discontinuation of the first biologic therapy because of adverse events was associate

60 New drugs and biologic therapies being developed for RA may thus find

61 infection who had started immunosuppressive biologic therapy both before and after 2009.

62 ic therapy (n = 183) and those who initiated biologic therapy but discontinued use (n = 42).

63 sthma so more effective immunomodulators and biologic therapies can emerge.

64 technologies have led to the development of biologic therapies capable of directly targeting selecte

65 Combination biologic therapy consisting of lenalidomide plus rituxim

66 ational data about the risk of infection and biologic therapy continue to emerge, although there are

67 These findings are important because biologic therapies could target epithelial-fibroblast in

68 Results from trials of other biologic therapies directed at tumor necrosis factor alp

69 tially higher than cost estimates before the biologic therapy era, and costs are now driven predomina

70 ction and symptoms of subjects who initiated biologic therapy (etanercept or infliximab) and reported

71 ients with a better prognosis should receive biologic therapies first, with transplant reserved until

72 ion and suicidal ideation in adolescents and biologic therapies for adolescent depression are reviewe

73 Newer biologic therapies for breast cancer such as trastuzumab

74 known about the drug survival of second-line biologic therapies for psoriasis in routine clinical pra

75 luation of the risk of serious infections in biologic therapies for psoriasis is lacking.

76 Makers of biologic therapies for psoriasis, whose products cost $1

77 As the array of biologic therapies for renal cancer expands with the app

78 er cancer chemotherapy, immunosuppressive or biologic therapies for the management of rheumatologic c

79 r 25 ongoing clinical trials on intravitreal biologic therapy for AMD, enthusiasm for vanguard biolog

80 antibodies, can potentially constitute a new biologic therapy for cancer patients.

81 In addition, advances in biologic therapy for Crohn disease are beginning to be f

82 al decision making when choosing second-line biologic therapy for patients with psoriasis.

83 Biologic therapy for pediatric IBD is an increasingly em

84 ous infections in people taking any licensed biologic therapy for psoriasis compared with those takin

85 l aid clinical decision making when choosing biologic therapy for psoriasis patients.

86 ivity or remission since the introduction of biologic therapy for RA.

87 in-2 pathways), and research on intravitreal biologic therapy for uveitis and AMD will continue to ex

88 </=90 kg or >90 kg) and previous exposure to biologics therapy for psoriasis.

89 Open-label extensions of biologic therapies found continued benefits extending se

90 Biologic therapies have increased the treatment options

91 and rheumatologic indications for long-term biologic therapies, HBV reactivation was not seen; this

92 is review is to summarize the recent data on biologic therapies in juvenile rheumatoid arthritis.

93 raditional immunomodulating as well as newer biologic therapies in management are continuing to be de

94 The majority of reports of biologic therapies in posterior uveitis have been uncont

95 tis looks bright with newer, highly targeted biologic therapies in the pipeline.

96 framework for the understanding of potential biologic therapies in the treatment of degenerative join

97 s review summarizes the current evidence for biologic therapies in the treatment of uveitis.

98 However, the study of biologic therapies in the vasculitides must be approache

99 It has been combined with chemotherapy and biologic therapy in an attempt to improve on this respon

100 The possibility of biologic therapy in large vessel vasculitis has emerged.

101 ancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unk

102 Biologic therapy in RA has significantly changed the cou

103 dical therapy is highlighted and more recent biologic therapies including the use of anti-tumor necro

104 Biologic therapies, including anti-tumor necrosis factor

105 y, the safety of different immunosuppressive biologic therapies, including rituximab, was assessed.

106 Biologic therapies, including the antitumour necrosis fa

107 ecifically, the introduction of intravitreal biologic therapies into clinical practice for uveitis, A

108 PURPOSE OF REVIEW: Since the introduction of biologic therapies into the treatment paradigm of rheuma

109 ic anti-inflammatory medications to targeted biologic therapies is reviewed.

110 Biologic therapy is associated with increased risk for s

111 sease-modifying antirheumatic drugs or newer biologic therapy is more effective.

112 vent of newer and emerging forms of targeted biologic therapies, it has become important to understan

113 ly to be increasingly deployed, and targeted biologic therapies may reduce the need for vascular inte

114 nd years 1 and 2 of therapy to those with no biologic therapy (n = 183) and those who initiated biolo

115 ential role for cIL-10 administration in the biologic therapy of cancer and suggests a broader interp

116 tial of genetically engineered cells for the biologic therapy of cancer.

117 considers testing for immunogenicity and how biologic therapy of psoriasis may be tailored on the bas

118 e with sensitivity to specific chemotherapy, biologic therapy, or other cancer treatments.

119 had not previously received methotrexate or biologic therapy received 50 mg of etanercept plus metho

120 tiple-dose study, patients who were naive to biologic therapy received infusions of tabalumab (30, 60

121 tologous stem cell transplantation, although biologic therapies seem to be promising.

122 gic therapy for AMD, enthusiasm for vanguard biologic therapies should be tempered by judicious monit

123 s, and focused on the application of TDM for biologic therapy, specifically anti-tumor necrosis facto

124 However, biologic therapies such as the B cell-depleting agent ri

125 Both prednisone and targeted biologic therapies such as tumor necrosis factor antagon

126 inase, inhibition of various chemokines, and biologic therapy such as hematopoietic stem cell transpl

127 tion in the airways of patients with asthma, biologic therapies targeted toward these type 2 pathways

128 anced disk imaging techniques, and the novel biologic therapies that presently have the most clinical

129 Newly developed biologic therapies that target prostate-cancer bone meta

130 Despite the enthusiasm in the field of biologic therapies, the majority of these new modalities

131 anisms of oral carcinogenesis and the use of biologic therapy to specifically target molecules altere

132 outpatients between 2001 and 2012 and taking biologic therapies, underwent evaluation of anti-HCV and

133 Rituximab is one of the earliest biologic therapies used in SLE.

134 Assessment of the risk of biologic therapy utilized conditional logistic regressio

135 year, while the cost for those not receiving biologic therapy was 6,164 US dollars.

136 verity Index at switching to the second-line biologic therapy were predictors of overall discontinuat

137 e psoriasis (phototherapy, oral systemic, or biologic therapies) were received by 27.3% of the total

138 compared with 28% in patients without use of biologic therapies, whereas inpatient costs didn't diffe

139 t methods for in vivo Treg expansion rely on biologic therapies, which are not Treg-specific and are

140 Bisphosphonate therapy implicating that the biologic therapy with an anti-TNF-alpha antibody might p

141 echniques will aid the target application of biologic therapy within the window of opportunity and ai

142 Initiating biologic therapy without trying triple therapy first inc